IP Library › Granted Patent US 12,442,000
Granted Patent B2
US 12,442,000 · App. 18/970,086 · Granted Oct 14, 2025

Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Inventors: Monic J. Stuart (Hillsborough, CA); Stephen Kelsey (Brookline, MA)
Assignee: Geron Corporation
C12N15/1135A61K47/543A61K47/549A61K49/0423B82Y5/00C12N2320/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,442,000
App. No.
18/970,086
Granted
Oct 14, 2025
Kind
B2
Abstract

Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having ET.

Claims (12)

1. A method for treating myelodysplastic syndrome (MDS) in a human, the method comprising:

administering an intravenous infusion of a therapeutically effective amount of imetelstat to the human, wherein the human has transfusion-dependent anemia and wherein the administering is effective to treat MDS in the human.

2. The method of claim 1 , wherein the human is resistant or intolerant to a prior non-telomerase inhibitor-based therapy.

3. The method of claim 1 , wherein the therapeutically effective amount of imetelstat is administered to the human every four weeks.

4. The method of claim 1 , wherein the imetelstat is administered with a pharmaceutically acceptable excipient.

5. A method for treating myelodysplastic syndrome (MDS) in a human, the method comprising:

administering an intravenous infusion of a therapeutically effective amount of imetelstat to the human every four weeks, wherein the human has transfusion-dependent anemia and wherein the administering is effective to treat MDS in the human.

6. The method of claim 5 , wherein the imetelstat is administered with a pharmaceutically acceptable excipient.

7. A method for alleviating at least one symptom associated with myelodysplastic syndrome (MDS) in a human in need thereof, the method comprising administering an intravenous infusion of a therapeutically effective amount of imetelstat to the human, wherein administration of the imetelstat alleviates at least one symptom associated with MDS.

8. The method of claim 7 , wherein the human is resistant to or intolerant to a prior non-telomerase inhibitor-based therapy.

9. The method of claim 7 , wherein the imetelstat is administered with a pharmaceutically acceptable excipient.

10. The method of claim 7 , wherein the imetelstat is administered every four weeks.

Assignments (3)
SECURITY INTEREST Recorded Mar 18, 2026
From: GERON CORPORATION
To: BIOPHARMA CREDITPLC, AS COLLATERAL AGENT
Reel/Frame 074115/0888 →
PATENT SECURITY AGREEMENT Recorded Mar 18, 2025
From: GERON CORPORATION
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 070551/0709 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2025
From: STUART, MONIC J.; KELSEY, STEPHEN
To: GERON CORPORATION
Reel/Frame 069757/0886 →
Continuity (12)
Continuation 17864129 · Jul 13, 2022
Continuation 17506499 · Oct 20, 2021
Continuation 17229298 · Apr 13, 2021
Continuation 17061276 · Oct 1, 2020
Continuation 16784931 · Feb 7, 2020
Continuation 16432727 · Jun 5, 2019
Continuation 16141464 · Sep 25, 2018
Continuation 15905577 · Feb 26, 2018
Continuation 15164582 · May 25, 2016
Division 13841711 · Mar 15, 2013
Provisional Application 61734941 · Dec 7, 2012
Related Publication 20250207136A1 · Jun 26, 2025
References Cited (318)
US 5583016A · Villeponteau et al. · 1996 [cited by applicant]
US 5656638A · Gaeta et al. · 1997 [cited by applicant]
US 5695932A · West et al. · 1997 [cited by applicant]
US 5760062A · Gaeta et al. · 1998 [cited by applicant]
US 5767278A · Gaeta et al. · 1998 [cited by applicant]
US 5770613A · Gaeta et al. · 1998 [cited by applicant]
US 5840490A · Bacchetti et al. · 1998 [cited by applicant]
US 5863936A · Gaeta et al. · 1999 [cited by applicant]
US 5952490A · Hanecak et al. · 1999 [cited by applicant]
US 5958680A · Villeponteau et al. · 1999 [cited by applicant]
US 6261836B1 · Cech et al. · 2001 [cited by applicant]
US 6331399B1 · Monia et al. · 2001 [cited by applicant]
US 6368789B1 · West et al. · 2002 [cited by applicant]
US 6444650B1 · Cech et al. · 2002 [cited by applicant]
US 6548298B2 · Villeponteau et al. · 2003 [cited by applicant]
US 6608036B1 · Gryaznov et al. · 2003 [cited by applicant]
US 7067497B2 · Hanecak et al. · 2006 [cited by applicant]
US 7321029B2 · Gryaznov et al. · 2008 [cited by applicant]
US 7485717B2 · Gryaznov et al. · 2009 [cited by applicant]
US 7494982B2 · Gryaznov et al. · 2009 [cited by applicant]
US 7563618B2 · Gryaznov et al. · 2009 [cited by applicant]
US 7989428B2 · Go et al. · 2011 [cited by applicant]
US 7989603B2 · Gryaznov et al. · 2011 [cited by applicant]
US 7998938B2 · Moore et al. · 2011 [cited by applicant]
US 8153604B2 · Deen et al. · 2012 [cited by applicant]
US 8377644B2 · Gryaznov et al. · 2013 [cited by applicant]
US 8440635B2 · Gryaznov et al. · 2013 [cited by applicant]
US 8906615B2 · Gryaznov et al. · 2014 [cited by applicant]
US 9133233B2 · Gryaznov et al. · 2015 [cited by applicant]
US 9375485B2 · Stuart et al. · 2016 [cited by applicant]
US 9388415B2 · Gryaznov et al. · 2016 [cited by applicant]
US 9404112B2 · Gryaznov et al. · 2016 [cited by applicant]
US 11123359B2 · Tefferi et al. · 2021 [cited by applicant]
US 20050113325A1 · Gryaznov et al. · 2005 [cited by applicant]
US 20050282893A1 · Au et al. · 2005 [cited by applicant]
US 20060009636A1 · Gryaznov et al. · 2006 [cited by applicant]
US 20060166221A1 · Bahou et al. · 2006 [cited by applicant]
US 20070015723A1 · Hanecak et al. · 2007 [cited by applicant]
US 20070224598A1 · Chang · 2007 [cited by applicant]
US 20070270363A1 · Bennett et al. · 2007 [cited by applicant]
US 20090162849A1 · Vainchenker et al. · 2009 [cited by applicant]
US 20090227681A1 · Dimock · 2009 [cited by applicant]
US 20100104586A1 · Tressler et al. · 2010 [cited by applicant]
US 20110263685A1 · Harley et al. · 2011 [cited by applicant]
US 20120322072A1 · Nygren · 2012 [cited by applicant]
US 20130253042A1 · Gryaznov et al. · 2013 [cited by applicant]
US 20140155465A1 · Bassett et al. · 2014 [cited by applicant]
US 20140163090A1 · Stuart et al. · 2014 [cited by applicant]
US 20140193518A1 · Sayeski et al. · 2014 [cited by applicant]
US 20140329890A1 · Gryaznov et al. · 2014 [cited by applicant]
US 20150005250A1 · Rollison et al. · 2015 [cited by applicant]
US 20150017119A1 · Fantl et al. · 2015 [cited by applicant]
US 20150299232A1 · Gryaznov et al. · 2015 [cited by applicant]
US 20150342982A1 · Stuart et al. · 2015 [cited by applicant]
US 20160287625A1 · Tefferi · 2016 [cited by applicant]
US 20170051287A1 · Stuart et al. · 2017 [cited by applicant]
US 20180036336A1 · Huang et al. · 2018 [cited by applicant]
CN 101220044 · 2008 [cited by applicant]
WO WO2001002377 · 2001 [cited by applicant]
WO WO2001018015 · 2001 [cited by applicant]
WO WO2002077184 · 2002 [cited by applicant]
WO WO2004029277 · 2004 [cited by applicant]
WO WO2005023994 · 2005 [cited by applicant]
WO WO2006113426 · 2006 [cited by applicant]
WO WO2007016354 · 2007 [cited by applicant]
WO WO2007128968 · 2007 [cited by applicant]
WO WO2008054711 · 2008 [cited by applicant]
WO WO2008112129 · 2008 [cited by applicant]
WO WO2010045245 · 2010 [cited by applicant]
WO WO2011098901 · 2011 [cited by applicant]
WO WO2013059738 · 2013 [cited by applicant]
WO WO2011017096 · 2014 [cited by applicant]
WO WO2014085632 · 2014 [cited by applicant]
WO WO2014088785 · 2014 [cited by applicant]
WO WO2014160071 · 2014 [cited by applicant]
WO WO2015069758 · 2015 [cited by applicant]
WO WO2016168612 · 2016 [cited by applicant]
WO WO2016207405 · 2016 [cited by applicant]
WO WO2018026646 · 2018 [cited by applicant]
WO WO2019023667 · 2019 [cited by applicant]
WO WO2020028261 · 2020 [cited by applicant]
U.S. Appl. No. 16/432,727 (Year: 2018). [cited by applicant]
European Search Report for EP 13861008.4 dated Aug. 22, 2016. [cited by applicant]
International Search Report for PCT/US2013/070437 dated Jan. 22, 2014. [cited by applicant]
Adams (1983) “Hindered dialkylamino nucleoside phosphite reagents in the synthesis of two DNA 51-mers” J. Am. Chem. Soc.; 105:661. [cited by applicant]
Asai et al. (2003) “A Novel Telomerase Template Antagonist (GRN163) as a Potential Anticancer Agent,” Cancer Res; 63:3931-3939. [cited by applicant]
Baerlocher et al. (2012) “Imetelstat rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) who are Refractory or Intolerant to Prior Therapy:Prelim… [cited by applicant]
Baerlocher et al. (2012) “Imetelstat: A Novel Approach with Robust Hematologic and Molecular Responses in a Phase 2 study in Patients with Essential Thrombocythemia (ET) who are Refractory or Intolerant to Prior Therapy… [cited by applicant]
Barbui et al. (2009) “Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?” Blood; 114:759-763. [cited by applicant]
Barosi et al. (2009) “Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference” Blood; 113(20):4829-4833. [cited by applicant]
Baxter et al. (2005) “Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders” Lancet; 365:1054-1061. [cited by applicant]
Beaucage (1981) “Deoxynucleoside phosphoramidites—A new class of key intermediates for deoxypolynucleotide synthesis” Tetra. Lett.; 22:1859. [cited by applicant]
Beer et al. (2010) “How I treat essential thrombocythemia” Blood; 117(5):1472-1482. [cited by applicant]
Belousov (1997) “Sequence-specific targeting and covalent modification of human genomic DNA” Nucleic Acids Res.; 5(25):3440-3444. [cited by applicant]
Blackburn (1992) “Telomerases” Ann. Rev. Biochem.; 61:113-129. [cited by applicant]
Blommers (1994) “Effects of the Introduction of L-Nucleotides into DNA. Solution Structure of the Heterochiral Duplex d(G-C-G-(L)T-G-C-G).cntdot.d(C-G-C-A-C-G-C) Studied by NMR Spectroscopy” Biochemistry; 33:7886-7896. [cited by applicant]
Brassat et al. (2011) “Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells,” Experimental Hematology; 39(1):66-76. [cited by applicant]
Briatore et al., (2009) “Increase of telomerase activity and hTERT expression in myelodysplastic syndromes” Cancer Biology & Therapy, 8(10): 883-889. [cited by applicant]
Brown (1979) “Chemical synthesis and cloning of a tyrosine tRNA gene” Meth. Enzymol.; 68:109. [cited by applicant]
Brunold et al. (2011) “Imetelstat, A Potent Telomerase Inhibitor, Inhibits the Spontaneous Growth of CFU-Meg In Vitro From Essential Thrombocythemia Patients but Not From Healthy Individuals,” Blood (444-456 ASH Annual … [cited by applicant]
Carobbio et al. (2007) “Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status” Blood; 109:2310-2313. [cited by applicant]
Carruthers (1982) “Chemical Synthesis and Biological Studies on Mutated Gene-control Regions” Cold Springs Harbor Symp. Quant. Biol.; 47:411-418. [cited by applicant]
Catenacci et al., (2005) “Myelodysplasic syndromes: A comprehensive Review”, Blood Reviews, 19:301-319. [cited by applicant]
Cazzola and Invernizzi, (2011) “Ring sideroblasts and sideroblastic anemias”, Haematologica, 96(6):789-792. [cited by applicant]
Chen et al. (2000) “Secondary Structure of Vertebrate Telomerase RNA” Cell; 100:503-514. [cited by applicant]
Della Porta and Malcovati, (2011) “Myelodysplastic syndromes with bone marrow fibrosis”, Haematologica, 96(2):180-183. [cited by applicant]
Drummond et al. (2005) “Dysregulated expression of the major telomerase components in leukemic stem cells,” Leukemia; 19:381-389. [cited by applicant]
El-Daly et al. (2005) “Selective Cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532,” Blood; 105(4):1742-1749. [cited by applicant]
El-Kassar et al. (1997) “Clonality Analysis of Hematopoiesis in Essential Thrombocythemia: Advantages of Studying T Lymphocytes and Platelets” Blood; 89:128-134. [cited by applicant]
Fialkow (1981) “Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell” Blood; 58:916-919. [cited by applicant]
Frenkel (1995) “12-dimethylbenz[a]anthracene induces oxidative DNA modification in vivo” Free Radic. Biol. Med.; 19:373-380. [cited by applicant]
Geron Corp (2012) “Geron discontinues GRN1005 and Restructures to Focus on Imetelstat Development in Hematologic Malignancies and Solid Tumors with Short Telomeres,” Press Release. [cited by applicant]
Geron Corp (2012) “Geron Corporation Reports Fourth Quarter and Annual 2012 Financial Results” Press Release. [cited by applicant]
Geron Corp (2013) “Geron Updates Imetelstat Development Strategy, Including Progress of Investigator-sponsored study in Myelofibrosis,” Press Release. [cited by applicant]
Geron Press Release (2012) “Geron Presents Positive Results from Phase 2 Study of Imetelstat in Essential Thrombocythemia at the American Society of Hematology Annual Meeting” Press Release. [cited by applicant]
Gianelli et al., (2012) “The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis”, Modern Pathology, 25:1193-1202. [cited by applicant]
Gnatenko et al. (2003) “Transcript profiling of human platelets using microarray and serial analysis of gene expression” Blood; 101:2285-2293. [cited by applicant]
Graubert et al., (2012) “Recurrent mutations in the U21AF1 splicing factor in myelodysplastic syndromes”, Nat Genet., 44(1):53-57. [cited by applicant]
Gryaznov and Letsinger (1992) “Synthesis and properties of oligonucleotides containing aminodeoxythymidine unites”, Nucleic Acids Research, 20(13):3403-3409. [cited by applicant]
Gryaznov and Lloyd (1993) “Modulation of oligonucleotide duplex and triplex stability via hydrophobic interactions”, Nucleic Acids Research, 21(25):5909-5915. [cited by applicant]
Gryaznov et al. (1996) “Oligonucleotide N3′→P5′ Phosphoramidates as antisense agents”, Nucleic Acids Research, 24(8):1508-1514. [cited by applicant]
Gryaznov and Winter (1998) “RNA Mimetics: oligonucleotide N3′→P5′ phosphoramidates”, Nucleic Acids Research, 26(18):4160-4167. [cited by applicant]
Gryaznov (1999) “Oligonucleotide N3′→P5′ Phosphoramidates as Potential Therapeutic Agents”, Biochimica et Biophysica Acta 1489:131-140. [cited by applicant]
Gryaznov et al. (2001) “Telomerase Inhibitors-Oligonucleotide Phosphoramidates as Potential Therapeutic Agents”, Nucleosides, Nucleosides & Nucleic Acids, 20(47):401-410. [cited by applicant]
Gryaznov et al. (2003) “Oligonucleotide N3′→P5′ Thio-phosphoramidate Telomerase Template Antagonists as Potential Anticancer Agents” Nucleosides, Nucleotides & Nucleic Acids; 22(5-8):577-581. [cited by applicant]
Gryaznov (2010) “Oligonucleotide N3′→P5′ Phosphoramidates and Thio-Phosphoramidates as Potential Therapeutic Agents”, Chemistry and Biodiversity, 7:477-493. [cited by applicant]
Gryaznov (2012) “Oligonucleotide N3′→P5′ Phosphoramidates and Thio-Phosphoramidates as Potential Therapeutic Agents”, in Chemistry and Biology of Artificial Nucleic Acids, Egli and Herdewijn Eds., Wiley-VCH, 2012, pp. 6… [cited by applicant]
Hanahan et al. (2011) “Hallmarks of Cancer: The Next Generation,” Cell; 144:646-674. [cited by applicant]
Harley (1991) “Telomere loss: mitotic clock or genetic time bomb?” Mutation Research; 256:271-282. [cited by applicant]
Harley et al. (1997) “Telomerase, Checkpoints and Cancer,” Cancer Surv.; 29:263-284. [cited by applicant]
Hennessy et al., (2005) “New Approaches in the Treatment of Myelofibrosis”, Cancer, 103(1):32-43. [cited by applicant]
Hochreiter et al. (2006) “Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer,” Clin. Cancer Res.; 12(10):3184-3192. [cited by applicant]
James et al. (2005) “A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera” Nature; 434:1144-1148. [cited by applicant]
Joseph et al. (2010) “The Telomerase Inhibitor Imetelstat Depletes Cancer Stem Cells in Breast and Pancreatic Cancer Cell Lines,” Cancer Research Online; 70:9494-9504. [cited by applicant]
Kakiuchi et al. (2010) “Inhibition of Human Tumor Cell Proliferation by the Telomerase Inhibitor TELIN”, Cytologia, 75(2):177-183. [cited by applicant]
Kelland (2005) “Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics,” Eur. J Cancer; 41:971-979. [cited by applicant]
Keller et al. (2009) “Telomeres and telomerase in chronic myeloid leukemia: impact for pathogenesis disease progression and targeted therapy,” Hematological Oncology; 27(3):123-129. [cited by applicant]
Kim et al. (1994) “Specific association of human telomerase activity with immortal cells and cancer,” Science; 266:2011-2014. [cited by applicant]
Kim et al. (2001) “A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation” Proc. Natl. Acad. Sci. USA; 98(14):7982-7987. [cited by applicant]
Kim et al. (2010) “Telomerase Activity is High in Essential Thrombocythemia and Polycythemia Vera, but Not in Myelofibrosis—a Comprehensive Analysis on Telomerase Activity and Cytogenetics in Myeloproliferative Neoplasm… [cited by applicant]
Kralovics et al. (2005) “A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders” N. Engl. J. Med.; 352:1779-1790. [cited by applicant]
Kupihar et al. (2001) “Synthesis and Application of a Novel, Crystalline Phosphoramidite Monomer with Thiol Terminus, Suitable for the Synthes” Bioorg. Med. Chem.; 9:1241-1247. [cited by applicant]
Lange et al., (2010) “Telomere Shortening and Chromosomal Instability in Myelodysplastic Syndromes” Genes, Chromosomes & Cancer 49, 260-269. [cited by applicant]
Lasho, et al. (2012) “SRSF2 Mutations in Primary Myelofibrosis: Significant Clustering with IDH Mutations and Independent Association with Inferior Overall and Leukemia-Free Survival”, Blood, 120(20):4168-4171. [cited by applicant]
Lee et al. (2003) “Telomere length shortening in non-Hodgkin's lymphoma patients undergoing chemotherapy,” Ann. Hematol. 82:492-495. [cited by applicant]
Lebedeva et al. (2001) “Antisense Oligonucleotides: Promise and Reality” Annual Review of Pharmacology and Toxicology; 41:403-419. [cited by applicant]
Levine et al. (2005) “Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis” Cancer Cell; 7:387-397. [cited by applicant]
Ly et al. (2005) “Functional characterization of telomerase RNA variants found in patients with hematologic disorders,” Blood; 105(6):2332-2339. [cited by applicant]
Macejak et al. (1999) “Adenovirus-Mediated Expression of a Ribozyme to c-myb mRNA Inhibits Smooth Muscle Cell Proliferation and Neointima Formation In Vivo” Journal of Virology; 73(9):7745-7751. [cited by applicant]
Makishima et al. (2012) “Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis” Blood; 119(14):3203-3210. [cited by applicant]
Maritz et al. (2010) “Targeting telomerase in Hematologic malignancy,” Future Oncology; 6(5):769-789. [cited by applicant]
McCurdy et al. (1997) “An Improved Method for the Synthesis of N3′→P5′ Phosphonamidite Oligonucleotides” Tetrahedron Letters; 38:207-210. [cited by applicant]
Meggendorfer , et al. (2012) “SRSF2 Mutations in 275 Cases with Chronic Myelomonocytic Leukemia (CMML)”, Blood, 120(15):3080-3088. [cited by applicant]
Mergny et al. (2002) “Natural and Phamacological Regulation of Telomerase”, Nucl. Acids Res., 30(4):839-865. [cited by applicant]
Mishra et al. (1995) “Improved leishmanicidal effect of phosphorotioate antisense oligonucleotides by LDL-mediated delivery” Biochim. Et Biophys. Acta; 1264:229-237. [cited by applicant]
Narang (1979) “[6] Improved phosphotriester method for the synthesis of gene fragments,” Meth. Enzymol.; 68:90. [cited by applicant]
Nelson et al. (1997) “N3′→P5′ Oligodeoxyribonucleotide Phosphoramidates: A New Method of Synthesis Based on a Phosphoramidite Amine-Exchange Reaction” J. Org. Chem.; 62:7278-7287. [cited by applicant]
Nimer (1999) “Essential Thrombocythemia: Another “Heterogeneous Disease” Better Understood?” Blood; 93:415-416. [cited by applicant]
Pallis et al. (2009) “The Telomerase Inhibitor RHPS4 Induces Telomere Shortening, DNA-Damage and Cell Death in AML Cells and Chemosensitises Cells to Daunorubicin”, Blood, 114(22):2760. [cited by applicant]
Papaemmanuil et al. (2011) “Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts” N Engl J Med. 365(15):1384-1395. [cited by applicant]
Pascolo et al. (2002) “Mechanism of Human Telomerase Inhibition by BIBR1532, a Synthetic, Non-nucleosidic Drug Candidate” J. Biol. Chem.; 277(18):15566-15572. [cited by applicant]
Pongracz and Gryaznov (1999) “Oligonucleotide N3′→P5′ thiophosphoramidates: synthesis and properties” Tetrahedron Letters; 49:7661-7664. [cited by applicant]
Pongracz et al. (2003) “Novel Short Oligonucleotide Conjugates as Inhibitors and Human Telomerase”, Nucleosides, Nucleotides & Nucleic Acids, 22(5-8):1627-1629. [cited by applicant]
Pruzan et al. (2002) “Allosteric inhibitors of telomerase: oligonucleotide N3′→P5′ phosporamidates,” Nucl. Acids Res.; 30(2):559-568. [cited by applicant]
Puri, et al. (2012) “Novel Therapeutics Targeting Telomerase and Telomeres,” J. Cancer Sci. Ther.; 5:e127. [cited by applicant]
Ratain et al. (2008) “A phase I trial of GRN163L (GRN), a first-in-class telomere inhibitor, in advanced solid tumors,” J. Clin. Oncol.; 26:3581. [cited by applicant]
Roth et al. (2003) “Telomerase is limiting the growth of acute myeloid leukemia cells,” Leukemia; 17(12):2410-2417. [cited by applicant]
Roth et al. (2007) “Short Telomeres and High Telomerase Activity in T-cell Prolymphocytic Leukemia,” Leukemi;a 21:2456-2462. [cited by applicant]
Roth et al. (2010) “Imetelstat (GRN163L)—telomerase-based cancer therapy,” Recent Results in Cancer Research; 184:221-234. [cited by applicant]
Ruden et al. (2013) “Novel anticancer therapeutics targeting telomerase,” Cancer Treatment Reviews; 39:1742-1749. [cited by applicant]
Ruden, et al. (2012) “Novel Therapeutics Targeting Telomerase and Telomeres,” J. Cancer Sci. Ther.; 5:e127. [cited by applicant]
Ruella et al. (2010) “Telomere length in pH-negative chronic myeloproliferative neoplasms: it is reduced according to JAK2 V617F mutation allele burden and it is not affected by cytoreductive treatment with hydroxyurea,… [cited by applicant]
Rump et al. (1998) “Preparation of Conjugates of Oligodeoxynucleotides and Lipid Structures and Their Interaction with Low-Density Lipoprotein” Bioconj. Chem.; 9:341-349. [cited by applicant]
Scheit (1980) “Nucleotide analogs: synthesis and biological function” John Wiley, New York. [cited by applicant]
Shaffer (2012) “Geron Hit Hard by Termination of Phase II Brain Cancer Trial,” Bioworld Today; 23(235):1, 4, 7. [cited by applicant]
Shammas, et al. (2008) “Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo”, Leukemia, 22:1410-1418. [cited by applicant]
Shay et al. (1997) “A survey of telomerase activity in human cancer”, Eur. J. Cancer; 33:787-91. [cited by applicant]
Shea et al. (1990) “Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates”, Nucl. Acids Res.; 18(13):3777-3783. [cited by applicant]
Shea-Herbert et al. (1999) “Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death”, Proc. Natl. Acad. Sci. USA 96(25): 14276-81. [cited by applicant]
Shea-Herbert et al. (2005) “Lipid modification of GRN163, an N3′→P5′ thio-phosphoramidate oligonucleotide, enhance the potency of telomerase inhibition”, Oncogene 24:5262-8. [cited by applicant]
Shea-Herbert et al. (2002) “Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors”, Oncogene 21:638-42. [cited by applicant]
Silver (2004) “Myelofibrosis: Thalidomide Finds a New Disease”, Mayo Clin. Proc., 79(7):857-858. [cited by applicant]
Spanoudakis et al. (2011) “Dynamics of Telomere's Length and Telomerawe Activity in Philadelphia Chromosom Negative Myeloproliferative Neoplasms”, Leukemia Research, 35(4):459-464. [cited by applicant]
Sumi et al. (2004) “A G-quadruplex interactive agent, telomestatin (SOT-095) induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia,” International Journal of Oncology; 24(6):… [cited by applicant]
Swedlow et al. (2008) “WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues”, Lyon, IARC Press. [cited by applicant]
Tauchi et al. (2003) “Activity of a Novel G-Quadruplex-Interactive Telomerase Inhibitor, SOT-095, Against Human Leukemia Cells” Involvement of ATM-Dependent DNA Damage Response Pathways. Blood, American Society of Hemat… [cited by applicant]
Tefferi et al. (2007) “Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms” Leukemia, 22:14-22. [cited by applicant]
Tefferi (2013) “Annual Clinical Updates in Hematological Malignancies: a Continuing Medical Education Series Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management” American Journal of Hema… [cited by applicant]
Tetsuzo et al., (2003) “Activity of a novel G-quadruplex-interactive telomerase inhibitor, SOT-095, against human leukemia cells: Involvement of ATM-dependent DNA damage response pathways”, [cited by applicant]
The Merck Manual (2007), Nikkei Business Publications, Inc., 1159-1162. [cited by applicant]
Theophile et al. (2008) “The expression levels of telomerase catalytic subunit hTERT and oncogenic MYC in essential thrombocythemia are affected by the molecular subtype,” Ann Hematol.; 87(4):263-8. [cited by applicant]
Thol, et al. (2011) “Prognostic Significance of ASXL1 Mutations in Patients with Myelodysplastic Syndromes”, J. Clin. Oncol. 29(18):2499-506. [cited by applicant]
Thompson et al. (2013) “A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL 1112),” Clinical Cancer Research; 1-7. [cited by applicant]
Tokcaer-Keskin et al., “The Effect of Telomerase Template Antagonist GRN163L on Bone-marrow-derived Rat Mesenchymal Stem Cells is Reversible and Associated with Altered Expression” Stem Cell Reviews and Reports, 6(2): 1… [cited by applicant]
Uhlmann and Peyman (1990) “Antisense oligonucleotides: a new therapeutic principle” Chemical Reviews; 90:543-584. [cited by applicant]
US National Institutes of Health (2010) “Open Label Study to Evaluate the Activity of Imetelstat in Patients with Essential Thrombocythemia or Polycythemia (ET/PV),” clinicaltrials.gov; NCT01243073. [cited by applicant]
US National Institutes of Health (2012) “Imetelstat Sodium in Treating Patients with Primary or Secondary Myelofibrosis,” clinicaltrials.gov; NCT01731951. [cited by applicant]
Van Ziffle (2003) et al. “Telomere length in subpopulations of human hematopoetic cells,” Stem Cells; 21:654-660. [cited by applicant]
Wang et al., (2004) “Telomerase inhibition with an oligonucleotide telomerase template antagonist; in vitro and in vivo studies in multiple myeloma lymphoma”, Blood, 103(1):258-266. [cited by applicant]
Ward and Autexier (2005) “Pharmacological Telomerase Inhibition Can Sensitize Drug-Resistant and Drug-Sensitive Cells to Chemotherapeutic Treatment” Mol. Pharmacol.; 68:779-786. [cited by applicant]
Wu et al. (1999) “Direct activation of TERT transcription by c-MYC”, Nature Genetics; 21:220-224. [cited by applicant]
Wu et al., (2010) “GRN163L, a telomerase inhibitor for cancer treatment” Chinese Journal of New Drugs, 19(2): Fig. 1. [cited by applicant]
Yasutaka et al., (2010) “Inhibition of Human Tumor Cell Proliferation by the Telomerase Inhibitor Telin” Cytologia, 75(2): 177-183. [cited by applicant]
Yoon et al. (2007) “Telomere length shortening of peripheral blood mononuclear cells in solid-cancer patients undergoing standard-dose chemotherapy might be correlated with good treatment response and neutropenia severi… [cited by applicant]
Zeng et al. (2003) “MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms” PNAS; 100(17):9779-9784. [cited by applicant]
Ziakas (2008) “Effect of JAK2 V617F on Thrombotic Risk in Patients With Essential Thrombocythemia: Measuring The Uncertain” Haematologica; 93:1412-1414. [cited by applicant]
Adema et al., (2013) “What lies beyond del(5q) in myelodysplastic syndrome?”, Haematologica, 98(12):1819-1821. [cited by applicant]
Ades et al., (2014) “Myelodysplastic Syndromes”, Lancet, 383(9936):2239-2252. [cited by applicant]
Almeida et al., (2017) “Recent Advances in the Treatment of Lower-Risk Non-del(5q) Myelodysplastic Syndromes (MDS)”, Leukemia Research, 52:50-57. [cited by applicant]
Baerlocher et al., (2015) “Supplementary Appendix”, New England Journal of Medicine, 373:1-41. [cited by applicant]
Baerlocher et al., (2019) “Imetelstat Inhibits Growth of Megakaryocyte Colony-forming Units From Patients with Essential Thrombocythemia”, Blood Advances, 3(22):3724-3728. [cited by applicant]
Baerlocher et al., (2015) “Telomerase inhibitor imetelstat in patients with essential thrombocythemia”, N Engl J Med, 373:920-928. [cited by applicant]
Beier et al., (2015) “Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide”, Leukemia Research, 39:1292-1298. [cited by applicant]
Bieche et al., (2000) “Quantitation of hTERT Gene Expression in Sporadic Breast Tumors with a Real-Time Reverse Transcription-Polymerase Chain Reaction Assay”, Clin Cancer Res, 6:452-459. [cited by applicant]
Blasco et al. (1997) “Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA”, Cell, 91:25-34. [cited by applicant]
Bruedigam et al., (2014) “Telomerase Inhibition Effectively Targets Mouse and Human AML Stem Cells and Delays Relapse Following Chemotherapy”, Cell Stem Cell, 15:775-790. [cited by applicant]
Bruedigam et al., (2016) “The preclinical efficacy of a novel telomerase inhibitor, imetelstat, in AML: A randomized trial in patient-derived xenografts”, QIMR Berghofer Medical Research Institute Study, presented at AS… [cited by applicant]
Cervantes, (2014) “How I treat myelofibrosis”, Blood, 124(17):2635-2642. [cited by applicant]
Clinical Trials, (2015) “Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)”, Geron Corporation, 20 pages, NC… [cited by applicant]
Clinical Trial, (2017) “Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)”, Janssen Research & Developm… [cited by applicant]
Crawford et al., (2009) “Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy”, Cancer 95(4):888-895. [cited by applicant]
Dong et al., (2016) “MDS shows a higher expression of hTERT and alternative splice variants in unactivated T-cells”, Oncotarget, 7(44):71904-71914. [cited by applicant]
Drevon et al., (2018) “Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myelodysplasies”, British Journ… [cited by applicant]
Ebrahim et al., (2016) “Hematologic malignancies: new strategies to counter the BCL-2 protein”, J. Cancer Res. Clin. Oncol., (142):2013-2022. [cited by applicant]
European Search Report issued in European Application No. EP16197293.0 dated Apr. 5, 2017. [cited by applicant]
Fenaux et al., (2011) “A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodsplastic syndromes with del5g”, Blood, 118(14):3765-3776. [cited by applicant]
Fenaux et al., (2017) “Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythrospiesis-Stimulating Agents (ESA) (Imerge)”, Blood, 130:4256. [cited by applicant]
Fenaux et al., (2013) “How we treat lower-risk myelodysplastic syndromes”, Blood, 121(21):4280-4286. [cited by applicant]
Fili et al., (2013) “Prospective phase II study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/int-1-risk myelodysplastic syndromes”, Clin Cancer res., 19(12):329… [cited by applicant]
Fischer et al., (2015) “Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options”, Nature Genetics, 47(9):1020-1029. [cited by applicant]
Fragkiadaki et al., (2022) “Telomerase inhibitors and activators in aging and cancer: A systematic review”, Molecular Medicine Reports, 25(158):1-11. [cited by applicant]
Garcia-Manero et al., (2011) “Hypomethylating agents and other novel strategies in myelodysplastic syndromes”, J. Clin Oncol., 29(5):516-523. [cited by applicant]
Gissingler et al., (2016) “Impact of High Molecular Risk Mutations on Overall Survival in WHO-Defined Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis”, Blood, 128(22):1931. [cited by applicant]
Greenberg et al., (1997) “International scoring system for evaluating prognosis in myelodysplastic syndromes”, Blood, 89(6):2079-2088. [cited by applicant]
Greenberg et al., (2012) “Revised International Prognostic Scoring System for Myelodysplastic Syndromes”, Blood, 120(12):2454-2465. [cited by applicant]
Guang et al., (2017) “Sulfated liposaccharides inspired by telomerase inhibitor axinelloside A”, Tetrahedron Letters, 58:4867-4871. [cited by applicant]
Guglielmelli et al., (2014) The Number of prognostically detriment mutations and prognosis in primary myelofibrosis: an international study of 797 patients, Leukemia, 28(9):1804-18010. [cited by applicant]
Haase et al., (2007) “New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients”, Blood, 110(13):4385-4395. [cited by applicant]
Harley et al., (1990) “Telomeres shorten during ageing of human fibroblasts”, Nature, 345:458-60. [cited by applicant]
Herbert et al., (2005) “Lipid Modification of GRN163, an N3′→P5′ thio-Phosphoramidate Oligonucleotide, Enhances the Potency of Telomerase Inhibition”, Oncogene, 24(33):5262-5268. [cited by applicant]
Hellstrom-Lindberg et al., (2003) “A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life”, B… [cited by applicant]
Hu et al., (2019) “Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells”, Blood, 13(134):1-14. [cited by applicant]
Huang et al., (2018) “New Drug Research and Development”, Journal of International Pharmaceutical Research, 45(177). [cited by applicant]
Hultdin et al., (1998) “Telomere analysis by fluorescence in situ hybridization and flow cytometry”, Nucl. Acids Res., 26(16):3651-3656. [cited by applicant]
International Search Report issued in PCT/US2017/044348 mailed Oct. 10, 2017. [cited by applicant]
International Search Report issued in PCT/US2018/044225 mailed Aug. 10, 2018. [cited by applicant]
Jafri et al., (2016) “Roles of Telomeres and Telomerase in Cancer, and Advances in Telomerase-targeted Therapies”, Genome Medicine, 8(69):10. [cited by applicant]
Jin et al., (2005) “Down Regulation of hTERT is an Important Mechanism in Apoptosis of MUTZ-1 Cells Induced by As203”, Blood, American Society of Hematology, 106(11):4910. [cited by applicant]
Kelaidi et al., (2013) “Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents”, Leukemia, 27(6):1283-1290. [cited by applicant]
Kishtagari et al., (2017) “Biological and clinical implications of telomere dysfunction in myeloid malignancies”, Ther Adv Hematol, 8(11):317-326. [cited by applicant]
Kroger et al., (2017) “Impact of molecular genetics on outcome in myelofibrosis patients after allogenic stem cell transplantation”, Biology of Blood and Marrow Transplantation, 23:1095-1101. [cited by applicant]
Kuykendall et al., (2022) “Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data”, Ann Hematol., 101:139-146. [cited by applicant]
Kuykendall et al., (2018) “Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation”, Annals of Hematology, 97:435-441. [cited by applicant]
Kuznar, (2021) “Imetelstat Has Disease-Modifying Activity in Relapsed/Refractory Myelofibrosis, as Shown by Effect on Telomerase Activity”, Onc Live, pp. 1-4. [cited by applicant]
Langabeer et al., (2016) “Chasing down the triple-negative myeloproliferative neoplasms: Implications for molecular diagnostics”, JAK-STAT, 5:e1248011-1-e1248011-5. [cited by applicant]
Leibundgut et al., (2015) “Dynamics of Mutations in Patients with ET Treated with Imetelstat”, Blood, 126(23):57. [cited by applicant]
Liu et al., (2017) “Arylsulfanyl groups—suitable side chains for 5-substitued 1, 10-phenanthroline and nickel complexes as G4 ligands and telomerase inhibitors”, Journal of Inorganic Biochemistry, 173:12-20. [cited by applicant]
Loiseau et al., (2015) “New therapeutic approaches in myelodysplastic syndromes: hypomethylating agents and lenalidomide”, Exp Hematol., 43(8):661-72. [cited by applicant]
Malcovati et al., (2006) “Predicting survival and leukemic evolution in patients with myelodysplastic syndrome”, Haematologica, 91:1588-1590. [cited by applicant]
Malcovati et al., (2005) “Prognostic factors and life expectancy in myelodysplastic sydromes classified according to WHO criteria: a basis for clinical decision making”, J Clin. Oncol., 23:7594-7603. [cited by applicant]
Marty et al., (2016) “Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis”, Blood, 127(10):1317-1324. [cited by applicant]
Mascarenhas et al., (2022) “Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design”, Future Oncol., 18(22):2393-2402. [cited by applicant]
Mascarenhas et al., (2018) “Imetelstat is effective treatement for patients with intermediate-2 or high-risk myelofibrosis who have relapsed on or are refractory to janus kinase inhibitor therapy: results of a phase 2 r… [cited by applicant]
Mascarenhas et al., (2021) “Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis”, J Clin Oncol., 39(26):2881-2892. [cited by applicant]
Mascarenhas et al., (2020) Telomerase activity, telomere length and hTert expression correlate with clinical outcomes in higher-risk myelofibrosis (MF) relapsed/refractory (R/R) to janus kinase inhibitor treated with im… [cited by applicant]
McNamara et al., (2019) “Long-term follow up of jak inhibitor (JAKI) treated patients with myelofibrosis: impact of molecular enhanced integrated scoring systems and type of JAKI therapy failure on survival”, EHA; Amste… [cited by applicant]
Mesa et al., (2016) “Individualizing Care for Patients with Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden”, Am Soc Clin Oncol Educ Book, 35:324-335. [cited by applicant]
Mosoyan et al., (2017) “Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis”, Leukemia, 31:2458-2467. [cited by applicant]
Mosoyan (2017) “Supplemental Figures”, Leukemia, 1-10. [cited by applicant]
Mosoyan (2017) “Supplemental Info”, Leukemia, 1-11. [cited by applicant]
Mudireddy et al., (2018) “Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons”, Bri J. Haematol., 182:594-597. [cited by applicant]
Newberry et al., (2017) “Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation”, Blood, 130(9):1125-1131. [cited by applicant]
Oliva et al., (2013) “Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study”, Ann Hematol, 92(1):25-32. [cited by applicant]
Palandri et al., (202) “Life After Ruxolitinib: Reasons for Discontinuation, Impact of Disease Phase, and Outcomes in 218 Patients with Myelofibrosis”, Cancer, 126(6):1243-1252. [cited by applicant]
Palma et al., (2013) “Telomere length and Expression of Human Telomerase Reverse Transcriptase Splice Variants in Chronic Lymphocytic Leukemia”, Experimental Hematology, 41:615-626. [cited by applicant]
Pardanani et al., (2014) “Definition and managment of ruxolitinib treatment failure in myelofibrosis”, Blood Cancer Journal, 4:e268. [cited by applicant]
Park et al., (2017) “Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents”, J Clin Oncol., 35(14):1591-1597. [cited by applicant]
Patel et al., (2015) “Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib”, Blood, 126(6):790-797. [cited by applicant]
Patnaik et al., (2015) “CME Information: Refractory anemia with ring sideroblasts and RARS with thrombocytosis”, Am. J. Hematol., 90(6):550-559. [cited by applicant]
Patnaik et al., (2017) “Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management”, American Journal of Hematology, 92(3):297-31… [cited by applicant]
Paulsson et al., (2007) “Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes”, Pathol Biol (Paris), 55:37-48. [cited by applicant]
Pettit et al., (2017) Novel therapies for myelofibrosis, Current Hematologic Malignancy Reports, 12:611-624. [cited by applicant]
Prebet et al., (2017) “Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy”, Oncotarget, 8(23):37866-37874. [cited by applicant]
Romero (2015) “Haematological Cancer—Promising Results of BCL2 Inhibition”, Nature Rev. Clin. Oncol., 12(9):504. [cited by applicant]
Ropio et al., (2016) “Telomerase Activation in Hematological Malignancies”, Genes, 7(9):61. [cited by applicant]
Rufer et al., (1998) “Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry”, Nature Biotechnology, 16:743-747. [cited by applicant]
Rumi et al., (2014) “Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis”, Blood, 124(7):1062-1069. [cited by applicant]
Rusbuldt et al., (2016) “Abstract 2731: Impact of hypomethylating agents on hTERT expression and synergistic effect in combination with imetelstat, a telomerase inhibitor, in AML cell lines”, Cancer Research, American A… [cited by applicant]
Santini et al., (2021) “On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythro… [cited by applicant]
Santini (2016) “Treatment of low-risk myelodysplastic syndromes”, Hematology Am Soc Hematol Educ Program, 1:462-469. [cited by applicant]
Schain et al., (2019) “Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population-based cohort study in Sweden and Norway”, Eur J Haematol., 103:614-619. [cited by applicant]
Shammo et al., (2016) “Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions”, Hematology Am Soc Hematol Educ Program, 2016(1):552-560. [cited by applicant]
Shreenivas et al., (2018) “Emerging drugs for the treatment of Myelofibrosis”, Expert Opinion on Emerging Drugs, 23(1):37-49. [cited by applicant]
Smith, (2010) “The clinical and economic burden of anemia”, Am J Manag Care, 16:S59-S66. [cited by applicant]
Sochacki et al., (2016) “Therapeutic approaches in myelofibrosis and myelodysplastic/myelolproliferative overlap syndromes”, Onco. Targets Ther., 9:2273-2286. [cited by applicant]
Sole et al., (2005) “Identification of novel cytogenic makrers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes”, Haematologica,, 90(9):1168-1178. [cited by applicant]
Spiegel et al., (2017) “Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy”, Blood Adv., 1(20):1729-1738. [cited by applicant]
Steensma et al., (2015) “Myelodysplastic syndromes: diagnosis and treatment”, Mayo Clinic Proc., 90(7):969-983. [cited by applicant]
Tefferi et al., (2013) “Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions in Myelofibrosis and Reversal of Bone Marrow Fibrosis”, Blood, 122(21):662. [cited by applicant]
Tefferi et al., (2015) “A pilot study of the telomerase inhibitor imetelstat for myelofibrosis”, N Eng J Med, 373(10):908-919. [cited by applicant]
Tefferi et al., (2014) “CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons”, Leukemia, 28:1472-1477. [cited by applicant]
Tefferi et al., (2016) “Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis”, Blood Cancer Journal, 6(3):1-2. [cited by applicant]
Tefferi et al., (2014) “Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis”, Blood, 124(16):2507-2513. [cited by applicant]
Tefferi et al., (2016) “Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management”, American Journal of Hematology, 91(12):1262-1271. [cited by applicant]
Tefferi et al., (2016) “The telomerase inhibitor imetelstat in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase (JAK) inhibitor: A phase 2, randomized study”, Journ… [cited by applicant]
Terrin et al., (2007) “Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same ig VH mutation status and different outcome”, Leukemia, 21:965-972. [cited by applicant]
The Merck Manual, (2007) 18th Edition, pp. 1098-1105. [cited by applicant]
Thepot et al., (2016) “A randomized phase II trial of azacitidine +/− epetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents”, Haematologica, 101(8):918-925. [cited by applicant]
Tobiasson et al., (2014) “Limited clinical efficacy of azacitidine in tranfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial”, Blood Cancer J., 4(e189): 1… [cited by applicant]
UNC School of Medicine, (2010) “History-Taking and Physical Examination”, Medicine Clerkship, 3 pages. [cited by applicant]
Vannucchi et al., (213) “Mutations and prognosis in primary myelofibrosis”, Leukemia, 27:1861-1869. [cited by applicant]
Vardiman et al., (2009) “The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes”, Blood, 114(5):937-951. [cited by applicant]
Vasko et al., (2017) “Telomeres and Telomerase in Hematopoietic Dysfunction: Prognostic Implications and Pharmacological Interventions”, Int J Mol Sci., 18(11):1-14, 2267. [cited by applicant]
Wang et al., (2014) “Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms”, Blood, 123(17): 2645-2651. [cited by applicant]
Wang et al., (2018) “Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells”, Blood Adv., 2(18): 2378-2388. [cited by applicant]
Xia, (2013) “Study on telomerase inhibitor Imetelstat that may be used for treatment of myelofibrosis”, Editorial Dept of Journal of Guangdong Pharmaceutical College, 29(6):639. [cited by applicant]
Zheng et al., (2017) “Triterpenoids from Ganoderma lucidum inhibit the activation of EBV antigens as telomerase inhibitors”, Experimental and Therapeutic Medicine, 14:3273-3278. [cited by applicant]
Zijlmans et al., (1997) “Telomeres in the mouse have large inter-chromosomal variations in the number of T2AG3 repeats”, Proc. Natl. Acad. Sci. USA, 94:7423-7428. [cited by applicant]